This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ARC LPA, AD-01765
Description: ARC-LPA is a RNAi therapeutic from the Dynamic Polyconjugate (DPC) delivery platform that is designed to reduce production of Lp(a).
Amgen and Arrowhead
Amgen and Arrowhead announced two license and collaboration agreements to develop and commercialize RNA interference (RNAi) therapies for cardiovascular disease. These are the first programs to utilize Arrowheads proprietary subcutaneous RNAi delivery platform.
Under one agreement, Amgen receives a worldwide, exclusive license to Arrowheads novel, RNAi ARC-LPA program. Under the second agreement, Amgen receives an option to a worldwide, exclusive license for a RNAi therapy for an undisclosed genetically validated cardiovascular target. In both agreements, Amgen will be wholly responsible for clinical development and commercialization.
Under the terms of the agreements taken together, Arrowhead will receive $35 million in upfront payments; $21.5 million in the form of an equity investment by Amgen in Arrowhead common stock; and up to $617 million in option payments, and development, regulatory and sales milestone payments. Arrowhead is...See full deal structure in Biomedtracker
Partners: Arrowhead Pharmaceuticals, Inc.
Additional information available to subscribers only: